Penumbra (PEN) Expected to Announce Earnings on Wednesday

Penumbra (NYSE:PEN) is expected to be posting its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Penumbra to post earnings of $0.90 per share and revenue of $340.7730 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.05. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The company had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. During the same period in the previous year, the company posted $0.64 EPS. The firm’s revenue for the quarter was up 13.4% compared to the same quarter last year. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Stock Performance

NYSE:PEN opened at $235.25 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75. Penumbra has a 52-week low of $206.51 and a 52-week high of $310.00. The firm has a market cap of $9.17 billion, a price-to-earnings ratio of 62.57, a PEG ratio of 2.24 and a beta of 0.41. The business’s fifty day moving average is $260.06 and its 200 day moving average is $260.48.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wall Street Zen upgraded Penumbra from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. UBS Group set a $335.00 price objective on Penumbra and gave the company a “buy” rating in a research note on Wednesday, July 30th. Royal Bank Of Canada decreased their target price on Penumbra from $330.00 to $325.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 30th. Citigroup decreased their target price on Penumbra from $320.00 to $285.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 9th. Finally, Truist Financial decreased their target price on Penumbra from $310.00 to $300.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Penumbra currently has a consensus rating of “Moderate Buy” and an average target price of $305.94.

Insiders Place Their Bets

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $249.70, for a total value of $149,820.00. Following the completion of the sale, the executive vice president owned 64,257 shares in the company, valued at approximately $16,044,972.90. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Harpreet Grewal sold 186 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $248.61, for a total value of $46,241.46. Following the completion of the sale, the director owned 8,702 shares of the company’s stock, valued at approximately $2,163,404.22. This trade represents a 2.09% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 64,460 shares of company stock worth $16,322,614. Insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Several institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of Penumbra by 139.4% in the 2nd quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock valued at $84,939,000 after purchasing an additional 192,734 shares during the period. Bank of America Corp DE lifted its stake in shares of Penumbra by 26.7% in the 2nd quarter. Bank of America Corp DE now owns 263,627 shares of the company’s stock valued at $67,655,000 after purchasing an additional 55,551 shares during the period. Man Group plc lifted its stake in shares of Penumbra by 1,862.2% in the 2nd quarter. Man Group plc now owns 206,461 shares of the company’s stock valued at $52,984,000 after purchasing an additional 195,939 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Penumbra by 55.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 157,492 shares of the company’s stock valued at $40,417,000 after purchasing an additional 56,076 shares during the period. Finally, Sei Investments Co. lifted its stake in shares of Penumbra by 34.6% in the 2nd quarter. Sei Investments Co. now owns 147,498 shares of the company’s stock valued at $37,853,000 after purchasing an additional 37,882 shares during the period. Hedge funds and other institutional investors own 88.88% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.